Disc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Barclays PLC

Barclays PLC boosted its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 123.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 40,145 shares of the company's stock after acquiring an additional 22,202 shares during the period. Barclays PLC owned about 0.14% of Disc Medicine worth $1,972,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in IRON. Amalgamated Bank raised its stake in Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company's stock valued at $26,000 after purchasing an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock worth $54,000 after buying an additional 337 shares in the last quarter. Quest Partners LLC purchased a new stake in shares of Disc Medicine during the third quarter worth $131,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Disc Medicine in the second quarter valued at about $129,000. Finally, Quantbot Technologies LP purchased a new position in shares of Disc Medicine in the third quarter worth about $146,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IRON has been the subject of a number of recent research reports. Morgan Stanley upgraded shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price objective for the company in a report on Tuesday, November 5th. Raymond James raised Disc Medicine from an "outperform" rating to a "strong-buy" rating and increased their price target for the company from $66.00 to $110.00 in a report on Monday, November 4th. Stifel Nicolaus lifted their price objective on Disc Medicine from $79.00 to $90.00 and gave the stock a "buy" rating in a research report on Tuesday, December 10th. Scotiabank upped their target price on Disc Medicine from $62.00 to $70.00 and gave the company a "sector outperform" rating in a report on Tuesday, November 5th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $87.50.

Disc Medicine Trading Down 2.2 %

NASDAQ IRON traded down $1.42 during trading hours on Friday, reaching $64.12. The company had a trading volume of 109,686 shares, compared to its average volume of 343,648. The stock has a market capitalization of $1.91 billion, a P/E ratio of -16.11 and a beta of 0.76. The stock has a 50-day moving average of $60.41 and a 200 day moving average of $51.45. Disc Medicine, Inc. has a 1-year low of $25.60 and a 1-year high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.15. As a group, sell-side analysts predict that Disc Medicine, Inc. will post -4.05 EPS for the current year.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 19,820 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $63.14, for a total transaction of $1,251,434.80. Following the sale, the chief executive officer now directly owns 72,065 shares in the company, valued at $4,550,184.10. This represents a 21.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director William Richard White sold 7,136 shares of the firm's stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The disclosure for this sale can be found here. Insiders have sold a total of 65,447 shares of company stock valued at $4,134,585 over the last quarter. 4.24% of the stock is owned by company insiders.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.